Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epanutin

- PMLiVE

Diabetes costs jump again in England

Cost of treating the disease rising as prices and patients increase in number

- PMLiVE

BMS launches Opdivo for lung cancer in UK

Drug to be called ‘Nivolumab BMS’ in the country

- PMLiVE

Pfizer and Flynn accused of overcharging for epilepsy drug

UK watchdog investigating the firms over the millions of pounds spent on Epanutin

- PMLiVE

Price tags on drug packs just ‘headline grabbing gimmick’

BMJ journal DTB says it could make cheaper drugs seem less important

- PMLiVE

FDA approves world’s first 3D printed drug

Aprecia’s epilepsy treatment Spritam seen as the future of drug manufacturing

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

healthcare data technology

Quarter of UK patients now diagnosing online

Survey finds people would rather self-diagnose symptoms than wait for GP appointment

- PMLiVE

Pharma must ‘create new social contract’

New task force established in UK to assess public’s view of the value and risk of medicines

- PMLiVE

Pfizer takes MRSA vaccine into phase IIb trial

Trial will involve patients undergoing elective spinal fusion surgery

- PMLiVE

AstraZeneca’s Amie Baker wins Communiquétor 2015 award

And the UK pharma company takes home In-House team of the Year

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links